Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Ronald Berenson | M | - |
Aequus BioPharma, Inc.
Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | 12 jaar |
Stewart D. Chipman | M | - |
Aequus BioPharma, Inc.
Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | - |
Frederick Telling | M | 73 |
Aequus BioPharma, Inc.
Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | - |
James A. Bianco | M | 67 |
Aequus BioPharma, Inc.
Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | - |
Jack W. Singer | M | 81 |
Aequus BioPharma, Inc.
Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | - |
David Cosman | M | - |
Aequus BioPharma, Inc.
Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 6 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Carl J. March
- Persoonlijk netwerk